Context Therapeutics (NASDAQ:CNTX) Upgraded to Hold at Wall Street Zen

Context Therapeutics (NASDAQ:CNTX) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

CNTX has been the subject of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Context Therapeutics in a research note on Wednesday, January 21st. D. Boral Capital reissued a “buy” rating and set a $9.00 price target on shares of Context Therapeutics in a report on Thursday, November 6th. HC Wainwright lifted their price objective on Context Therapeutics from $4.00 to $5.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Finally, Jones Trading assumed coverage on Context Therapeutics in a research report on Monday, December 22nd. They set a “buy” rating and a $7.00 target price on the stock. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Context Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.00.

Context Therapeutics Trading Up 5.7%

Shares of CNTX stock opened at $2.61 on Friday. The company has a market capitalization of $239.81 million, a P/E ratio of -10.88 and a beta of 1.91. The business’s 50 day moving average is $1.40 and its two-hundred day moving average is $1.13. Context Therapeutics has a twelve month low of $0.49 and a twelve month high of $2.85.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). As a group, equities analysts predict that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Context Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of CNTX. Clear Harbor Asset Management LLC boosted its stake in shares of Context Therapeutics by 60.5% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock worth $90,000 after acquiring an additional 35,000 shares in the last quarter. Vanguard Group Inc. raised its holdings in Context Therapeutics by 4.0% during the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after purchasing an additional 134,449 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new stake in Context Therapeutics during the third quarter worth $100,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.